# Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

> **NCT00093158** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 13800 (—)

## Conditions studied

- Unstable Angina
- Myocardial Infarction
- Acute Disease

## Interventions

- **DRUG:** Angiomax (bivalirudin) anticoagulant

## Key facts

- **NCT ID:** NCT00093158
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 13800 (—)
- **Last updated:** 2007-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093158, "Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00093158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*